Review Article

Integrated Approaches in Modern Medicine: A Comprehensive Study Of Disease Mechanisms, Clinical Management, and Innovative Healthcare Strategies

Jackson Daniel[1], Dr Pranjal Upadhayay[2], Dr. Ameet H[3], Dr. Sheena. P. Kochumon[4], Dr. Annapurna C Reddy[5], Vikas Singh[6], Bikash Choudhury[7]

[1]professor, Biomedical Engineering, KIT - Kalaignarkarunanidhi Institute of Technology, Coimbatore.
[2]District immunization officer, Department of Health and Medical Education Madhya Pradesh.
[3]Assistant Professor, Department of Respiratory Medicine, Malla Reddy Vishwavidyapeeth, Malla Reddy Institute of Medical Sciences, Hyderabad.
[4]Department of Paediatrics, Amrita Institute of Medical Sciences and Research Centre, Amrita School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
[5]Vice Dean Faculty of Nursing, Integral University, Lucknow, 226026.
[6]Professor, Department of public health Dentistry, Teerthanker Mahaveer Dental College & Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
[7]Research Scholar, Dhamma Dipa International Buddhist University, Sabroom, South Tripura.
Emails: Jacksdani74@gmail.com, pranjalupadhayay94@gmail.com, ygkreddykanna@gmail.com, sheenspk@gmail.com, ameetharishkumardr@gmail.com, drvikas7@gmail.com, bikashchoudhuryddibu@gmail.com

Abstract

Modern medicine is currently undergoing a paradigm shift from organ- and disease-oriented concepts to integrated approaches by linking molecular, clinical, therapeutic, technological, and population health domains. This shift is dictated by the fact that the majority of morbidity and mortality factors are complex traits and processes with multiple etiologies, outcomes, and mechanisms. Most diseases are determined by genetic, epigenetic, immune, metabolic, environmental, behavioral, aging-related, and socioeconomic individual factors, as well as their interactions. The burden of noncommunicable diseases increases due to persistent inflammation foci, while antimicrobial resistance, emerging pathogens, and the complexity of polyetiologic syndromes deteriorate the situation with global health security. This requires new approaches to understand the nature of the problems and offer integrated solutions. The present narrative review focuses on three central aspects of modern medicine and the current trends in basic science, clinical practice, and integrated health care strategies. First, the main mechanisms of disease include genomic, epigenetic, inflammatory, immunological, mitochondrial, metabolic, senescence-related, and microenvironmental processes as well as dysbiosis of the commensal microbiota. Second, the contemporary clinical practice increasingly emphasizes personalized and precision-oriented considerations, such as diagnosis and prognosis of disease using biomarkers, molecular mechanisms, and genetic variation, the development of therapeutic strategies, multidisciplinary care, disease prevention, and surveillance. Third, the new technological platforms such as AI, multi-omics, telemedicine, digital biomarkers, liquid biopsy, advanced imaging, gene editing, cell therapy, organoids, and learning health care systems can harness the opportunities of data science, including machine learning, for better health care. Nevertheless, there is a need for cautious adoption of these opportunities, with a particular emphasis on proper validation, implementation, surveillance, and regulation, as well as ethical, effective, equitable, affordable, and sustainable solutions within the context of human expertise.

Thus, medicine may enter a new era when the convergence of basic science and clinical practice guided by informatics and data science will transform health care through better detection, characterization, prediction, and management of disease while emphasizing prevention and patient-centered care.

Keywords: integrated medicine; disease mechanisms; precision medicine; clinical management; artificial intelligence; genomics; immunology; digital health; personalized healthcare; gene therapy; healthcare innovation.

1. Introduction

Although there have been tremendous scientific advancements, there are several challenges that have been identified that would determine whether integrated medicine is a clinically relevant phenomenon.

The first limitation is biology, or the complexity of it, as many diseases originate from interactional networks, hence multiple biological processes.

The second limitation is heterogeneity, which refers to the fact that a successful treatment for one particular molecular category may not be tolerated or even received poorly by another.

The third limitation comes in the form of evidence, which means that newer technologies should not be evaluated

on their technical capabilities but rather on how they affect established clinical processes and outcomes.

The fourth limitation is the current state of the healthcare ecosystem as it exists today, which is fragmented, and molecular stratification becomes irrelevant if there is no connectivity across the system.

The fifth limitation is related to the deluge of data that is available or being generated on a global scale, which has led to the realization that data abundance does not always translate into clinical intelligence.

The sixth challenge is affordability and accessibility, making sure equitable treatment is possible; if those aspects are not addressed, modern medicine only works for the select few, leaving everyone else with inadequate care.

Lastly, in terms of making integrated medicine a reality and precision medicine, there will always be clinical uncertainty, and although probabilities will shift, an absolute certainty will not become a characteristic of the discipline, and communication will remain as relevant as the technology itself.

This fact is dictated by the current global health security needs since the world population is challenged by chronic diseases, which impose a significant burden on societies. According to the WHO report, noncommunicable diseases (NCDs) kill 43 million people each year, which constitutes 75% of all deaths from preventable causes. From these causes, cardiovascular diseases constitute the largest category, with neoplasms, chronic obstructive pulmonary diseases, and diabetes mellitus following. Since the majority of NCD-related deaths occur now in low- and middle-income countries, the matter of health security becomes even more pressing. Indeed, human health is inseparable from socioeconomic and environmental concerns, and multidisciplinary approaches, including policy research and community development, are needed.1

However, the problem of infectious diseases is no less relevant, as sepsis is a syndrome that kills millions of people worldwide due to secondary infections. Moreover, the threat of untreatable bacterial infections that are resistant to antibiotics is growing, which significantly limits the clinicians' ability to manage critically ill patients and impacts the implementation of transplantology, oncology, and intensive care. According to the WHO statistics, one out of six laboratory-diagnosed resistant bacterial infections worldwide was recorded in 2023, which illustrates the complexity of health services management issues that antimicrobial resistance (AMR) presents.4,5

In this regard, today's medicine operates in multiple domains, encompassing various aspects of biology, clinical individual practice, and social communities. Treating the disease successfully requires combined individual and global approaches; clinicians must choose therapies at the level of cells, tissues, and organs and ensure access to care, adherence to treatment, and social support. In this article, selected health issues will be discussed, including diverse mechanisms involved in the pathophysiology of several diseases, some treatment approaches, and recent advances in health care.

2. Approach to the Review

This article contains a narrative and integrative review of the literature. In addition to recent peer-reviewed articles, leading clinical and translational research reviews, and clinical guidelines from local and international regulatory and health agencies were included as part of the preparatory work. Particular attention was paid to recently published and breakthrough discoveries that are relevant to the review and allow forecasting trends up to 2026. In turn, current research findings were related to the general scientific and clinical background.
The review was organized around three questions:

1. What molecular and cellular mechanisms are common for the majority of human diseases?
2. How may understanding these mechanisms help in the diagnosis, prevention, treatment, and long-term follow-up of diseases?
3. What new technologies and healthcare systems do you think will have the most significant impact on the future of medicine?

3. Disease Mechanisms: From Molecular Abnormalities to Systemic Disease

3.1 Genetic and Genomic Alterations

Genetic variation is one of the most important factors determining the ways and degrees of disease susceptibility. Variations of individual genes may be the reason why a person gets diagnosed with any of the monogenic syndromes, while such common diseases as diabetes, hypertension, coronary artery disease, autoimmune disease, or cancer are usually caused by the interaction of several genes and a person's behavior, lifestyle or demography.

Genomic variation plays a significant role in cancer since tumor formation is the result of a series of clonal selection events causing cells to gain multiple pro-tumorigenic properties advantageous for proliferation, survival, invasion, the metabolism of various substances, immunosurveillance, and resistance to treatment. For this reason, tumors of the same origin can have distinct clinical behaviors and appear different under the microscope, which led to the development of the increasingly detailed classification systems based on molecular traits. Therefore, the new wave of drugs for treating advanced non–small-cell lung cancer has already appeared; several biomarkers can be detected to identify a tumor's genomic profile for each individual patient so that the physician prescribes the drugs targeting specific genes, molecules, or proteins responsible for tumor progression and malignancy. The list of targets includes EGFR, ALK, ROS1, RET, MET, KRAS, NTRK, BRAF, ERBB2, or other kinases, depending on the mutations detected in tumor cells. In addition to oncology, precision medicine allows monitoring or treating a variety of diseases caused by genetic variations in individual genes or entire chromosomes. For instance, the principles of personalized medicine can be used in patients with inherited cardiovascular diseases, neuromuscular syndromes, pharmacogenomic variants, metabolic diseases, or heritable predispositions to cancer to determine the most effective therapeutic strategy. However, genetic testing findings are not always directly connected to the specific gene, mutation, or chromosomal abnormality. The same genotype can produce different phenotypes due to phenotypic plasticity or interact with penetrance, epigenetics, modifier genes, ethnicity, lifestyle, environment, or aging. Therefore, genetic test results must be evaluated by a professional who will determine the best course of action for the patient.

3.2 Epigenetic Regulation

Epigenetic mechanisms may control genes by various means, leaving the DNA sequence intact. DNA methylation, histone modification, chromatin remodeling, and regulatory RNAs play a role in cell identity and function and are involved in the immune response, metabolism, development, and aging and are linked to carcinogenesis.

Environmental factors can affect epigenetic regulation of genes and contribute to the etiology of the disease. The factors that affect epigenetic regulation include nutrition, smoking, environmental pollution, stress, infection, aging, and inflammation. Thus, the key role of epigenetics is the regulation of physiological processes, and a defect in these regulatory mechanisms can lead to the pathophysiology of many diseases.

The ability to intervene in epigenetic processes is therapeutically relevant in cases where specific genes are aberrantly silenced or activated. Consequently, some existing cancer therapies are epigenetic drugs; moreover, there is a search for such treatments for other diseases. At the same time, epigenetic marks are being studied as potential biomarkers for cancer, aging, prognosis, and therapy monitoring.

Thus, the interaction between genes and the environment is not as simple as was previously thought. Both genes and the environment influence each other since the environment can affect epigenetic marks and, thus, gene expression. On the other hand, genetic makeup can affect the individual's response to environmental factors.

3.3 Inflammation as a Common Pathological Pathway

The role of inflammation is paradoxical: on the one hand, it is a protective response that eliminates pathogens and repairs damaged tissues; on the other hand, dysfunctional inflammation promotes disease.

Atherosclerosis is initiated by the retention and modification of atherogenic lipoproteins in the vascular wall, leading to endothelial dysfunction and triggering innate and adaptive immunity. Monocytes traffic into the vessel wall, where they differentiate into macrophages, accumulate lipids, and contribute to lesion development in the form of fatty streaks and atherosclerotic plaques. The progression of atherosclerosis is complicated by the crosstalk between proinflammatory pathways and those of hemostasis, leading to fibrous cap destabilization and plaque rupture, resulting in myocardial infarction.

Adipose tissue is an endocrine organ whose functions are regulated by adipocytes and immune cells. Pro-inflammatory adipokines control insulin sensitivity, vascular tone, hepatic glucose production, and systemic inflammation; thus, being critically implicated in the development of metabolic syndrome and autoimmune disorders. Studies on immunometabolism have advanced understanding of the crosstalk between immune cells and metabolic processes, as well as demonstrated the role of mitochondria and metabolites in the regulation of inflammatory responses 5 .

Chronic inflammation seems to play a crucial role in tumorigenesis. It may drive the accumulation of genetic mutations by promoting excessive proliferation of mutant cells, supporting the transformation of tumor stroma and vasculature, and contributing to tumor immunity evasion.

Dysregulated inflammation is also involved in the pathogenesis of neurological disorders. Although amyloid pathology was long considered the main culprit in Alzheimer's disease etiology, recent studies highlight the importance of the interaction between CNS resident immune cells and peripheral myeloid cells, as well as blood-brain barrier dysfunction, genetic, metabolic, and inflammatory disruptions, in driving pathological changes in Alzheimer's disease 6 .

Overall, the examples described above highlight the notion of the dual nature of the inflammatory response. Proinflammatory factors that promote the development of one disease can protect against another by regulating diverse downstream processes in various cell types. Thus, when considering the possibility of targeting inflammation for therapeutic benefit, it is essential to keep in mind the heterogeneity of proinflammatory pathways in different disease settings and take into account temporal, tissue-specific, cellular, and pathophysiological factors.

3.4 Immune Dysregulation and Loss of Tolerance

Autoimmune diseases occur as a result of loss of immunological tolerance to self-antigens and/or inappropriate downregulation of effector responses that are aimed at self-antigens.

Genetic, infectious, microbiome, hormonal, environmental, molecular mimicry, tissue damage, and stochastic factors can contribute to autoimmunity. Dysregulated B cells, T cells, and innate immunity effector functions can each cause autoimmunity through production of pathogenic autoantibodies, cytotoxicity, and cytokine-driven inflammation, respectively.

It is noteworthy that there are common mechanisms of autoimmunity that are dysregulated in many autoimmune diseases leading to the development of therapeutics targeting similar pathways despite the clinical heterogeneity of autoimmune diseases.

A prominent example of such an approach is engineered cellular therapeutics, an emerging field in immunology. Chimeric antigen receptor T cell technology, initially developed for the treatment of tumors, has been utilized for the modulation of pathogenic B-cell responses in several autoimmune diseases that are refractory to conventional treatment modalities. Nevertheless, the therapeutic window of such treatments and their manufacturing feasibility, as well as the overall benefit-risk balance versus other therapeutics, should be further elucidated.7

3.5 Mitochondrial and Metabolic Dysfunction

Mitochondria are multifunctional organelles that play an integral role in a cell through their involvement in such vital processes as ATP production, regulation of cell death (apoptosis), and response to different stressors. Mitochondria participate in other significant physiological processes, including apoptosis, cellular signaling, calcium homeostasis, innate immunity, metabolic adaptation, and response to stress (1).

The dysfunction of mitochondria often takes part in cardiometabolic diseases, cancer, neurodegenerative and neurodevelopmental disorders, primary mitochondrial disease, and aging. The malfunction of mitochondria can lead to the development of diseases because of the inability to maintain healthy energy metabolism, the appearance of reactive oxygen species, mitochondrial genome instability, the alteration in mitochondrial dynamics, inappropriate mitophagy, calcium homeostasis, and metabolite profiling (2). The role of mitochondria in several diseases, specifically type 2 diabetes and cancer, has been established (8). Researchers argue that in type 2 diabetes, insulin resistance develops as a result of the interaction between adipose tissue, genetic, pro-inflammatory pathways, lipid metabolism, hepatic glucose production, skeletal muscle glucose uptake, pancreatic functionality, and the neuroendocrine system. Additionally, the failure of beta-cells to increase insulin secretion in response to hyperglycemia may lead to the development of diabetes (1).

On the other hand, cancer cells reprogram their physiology to meet the demand for alternative nutrients and adapt to the stressful conditions of the microenvironment and survive treatment. This process allows tumor cells to evade immune surveillance and develop resistance to therapeutics, which leads to treatment failure and disease progression (9). Therefore, the relationship between metabolism and immunity emerges as a key player in modern biology.

3.6 Cellular Senescence and Biological Ageing

Age presents one of the most prominent risk factors for the development of cardiovascular diseases, cancer, neurodegeneration, metabolic disorders, frailty, and many other pathological conditions associated with inflammation.

The hallmark pro-aging processes include genome instability, deregulation of epigenetic information, impairment of

proteostasis, reduced autophagy, mitochondrial dysfunction, deregulation of cellular nutrient sensing pathways, cellular senescence, exhaustion of tissue-specific stem cells, chronic inflammation, and altered inter-cellular communication.

One of the hallmarks of aging is cellular senescence, which is irreversible cell cycle arrest associated with persistent metabolic activity. Cells that undergo senescence can acquire a pro-inflammatory secretory phenotype that remodels the extracellular environment with deleterious consequences for the organism.10

There is an extensive and growing body of literature demonstrating that each of the pro-aging processes mentioned can be successfully targeted by specific therapeutic interventions. Careful analysis of the available evidence suggests that despite the promising results, caution should be exercised in interpreting these findings and designing clinical trials in humans due to the complexity of the biological system and the absence of standardized biomarkers of aging. Indeed, successful targeting of specific processes in a given model does not necessarily lead to an overall favorable outcome in terms of health span or life span.11

3.7 Microbiome-Host Interactions

Humans live in symbiosis with numerous microorganisms that inhabit their bodies, primarily the GI tract, skin, oral cavity, upper respiratory tract, and other areas. Commensal microorganisms are involved in the digestion process, the functioning of the skin and mucous membranes, the immune system, defense against pathogens, the production of certain metabolites with antibacterial properties, and other processes.

The role of the microbiota in health and disease is difficult to overestimate. Dysbiosis is associated with the development of inflammatory bowel disease, obesity, metabolic syndrome, cancer, allergies, autoimmune diseases, and numerous other conditions. Many bacterial metabolites traditionally affect the physiology of the epithelium and the immune system; among them are short-chain fatty acids.12,13

However, it is often complicated to establish a causal relationship between changes in the microbiota composition and health outcomes. The reason for this is that shifts in the microbiota can be provoked by a large number of factors outside the body: the use of certain drugs, nutritional interventions, geographical location, age, different stages of disease, and many others. When examining the potential of the microbiome, some of these factors were taken into account, which weakened the causal link between them and health outcomes.14

Thus, although groundbreaking, microbiome research is associated with several challenges related to interpreting the results and establishing causal relationships between interventions and health outcomes. In particular, to understand the mechanisms of action, it is necessary to conduct standardized trials and adjust for possible confounding factors.

4. Representative Integrated Disease Models

Disease domain	Important interacting mechanisms	Clinical implication
Cardiometabolic disease	Genetics, adiposity, insulin resistance, inflammation, endothelial dysfunction, renal disease, neurohormonal activation	Management should address multiple cardiovascular, renal, metabolic, and behavioral risks
Cancer	Genomic instability, clonal evolution, altered metabolism, immune escape, microenvironment, angiogenesis	Molecular profiling and biomarker-guided therapy increasingly complement histology
Severe infection/sepsis	Pathogen virulence, innate and adaptive immunity, endothelial injury, coagulation, metabolic failure, organ dysfunction	Rapid diagnosis, appropriate antimicrobials, source control and physiologic support must occur together
Autoimmune disease	Loss of tolerance, B- and T-cell dysregulation, cytokine signaling, genetics, environmental triggers	Therapy can target specific immune pathways rather than only symptoms

Disease domain	Important interacting mechanisms	Clinical implication
Neurodegeneration	Protein abnormalities, synaptic dysfunction, genetics, ageing, vascular injury, mitochondrial dysfunction, neuroinflammation	Multifactorial risk reduction and multimodal disease modification may be required

These examples demonstrate why single-mechanism explanations frequently become insufficient as knowledge advances. Disease phenotypes often represent the final clinical expression of several interacting biological networks.

5. Clinical Management in Modern Medicine

5.1 Prevention as a Clinical Intervention

Integrated medicine begins before the clinical manifestation of the disease.

Primary prevention includes various measures such as vaccination, tobacco control, nutritional and exercise programs, environmental safety, infection control, blood-pressure reduction, and exposure reduction. The main goal of secondary prevention is to treat a condition early enough to prevent the development of overt disease or reduce complications. Tertiary prevention aims to reduce the severity and impact of an illness.

Modern prevention is shifting towards becoming more individualized. The assessment of an individual's risk of disease can include conventional risk factors such as age, blood pressure, tobacco use, family history, body mass index, and laboratory values, as well as information from imaging, biomarker, genomic, environmental, and other health assessments.

Precision public health can be viewed as an extension of individual prevention into the domain of population health, by attempting to match individuals to interventions most likely to help them on the basis of genetic, environmental, behavioural, social, and other factors.

However, prevention is not going to work if it is not equitable. There is little point in pursuing increasingly sophisticated individual risk assessment if basic screening tests, vaccines, medications, or treatments are inaccessible to many populations.

5.2 Integrated Diagnosis

The traditional diagnostic model relies on clinical history, physical examination, laboratory tests, imaging, pathology, and microbiology. These remain foundational, but diagnostic medicine increasingly incorporates several additional layers.

Molecular diagnostics

Genomic sequencing, transcriptomics, proteomics, metabolomics, and epigenomic testing can identify biological subtypes that are not obvious from conventional phenotypes.

Advanced imaging

Artificial intelligence-assisted imaging, functional imaging, molecular imaging, and quantitative radiology can provide information beyond anatomical structure.

Liquid biopsy

Analysis of circulating tumor DNA, circulating cells, extracellular vesicles, proteins, and other biomarkers can enable cancer detection, characterization, the assessment of minimal residual disease, and recurrence monitoring. The problem is that more sensitive assays will inevitably lead to the identification of incidental findings, not all of which will be immediately actionable. Thus, cancer screening research will focus on biomarker discovery, individual risk assessment, biological and analytical validity, and the clinical implications of screening results.16

Longitudinal biomarkers

While a single measurement can provide valuable information, serial measurements can often provide more information. Trends in glucose levels, blood pressure, renal function, inflammatory markers, cardiac rhythms, weight, or disease-specific parameters, may be more informative than individual data points.

The future therefore lies in longitudinal and multimodal diagnostic testing, rather than in isolated tests

6. Precision and Integrated Pharmacological Management

6.1 Precision and Personalized Therapeutics

Precision medicine seeks to optimize prevention or treatment based on characteristics of the individual patient or a biologically defined subgroup.

The field is most advanced in oncology, where biomarkers can guide therapeutic and immunotherapeutic agent selection, but similar opportunities are now being explored for monogenic diseases, pharmacogenomics, autoimmunity, infection, and cardiometabolic risk.

Although precision medicine is sometimes confused with the notion of personalized medicine, it usually refers to the improved stratification of patients into categories that differ in prognosis or treatment response.

This requires combining clinical and genetic data, which are challenging to harmonize across centers because of informatics, governance, privacy, security, and data-ownership issues.

Meanwhile, methodological consistency across studies is critical, and reporting standards such as BePRECISE have been proposed to address the problem of heterogeneity in published work.

6.2 Integrated Pharmacological Management

Nowadays, pharmacological therapy is more inclined to targeting mechanisms rather than symptoms.

The treatment of cardiometabolic disease increasingly recognizes the need to simultaneously address multiple risk factors including blood pressure, lipids, glucose, renal function, prothrombotic state, smoking, physical activity, and body weight because beyond the control of single risk factor, a comprehensive reduction of overall atherosclerotic cardiovascular disease and renal risk is required.

The management of cancer applies surgery, radiotherapy, cytotoxic and molecularly targeted chemotherapy, immunotherapy, endocrine, and cell therapy depending on tumor type, stage, molecular characteristics, patient's condition, and desired outcomes.

The treatment of autoimmune diseases obeys the use of biologics and small molecules targeting key pro-inflammatory cytokines, cell receptor pathways, transcription factors, and cell populations.

The control of the infectious disease combines the identification and isolation of cases, etiological treatment by antimicrobials, chemotherapy, supportive treatment, and immunomodulatory therapy following the principles of infection control, surveillance, vaccination, and antimicrobial stewardship.

As a result, the choice of therapy involves intricate considerations about the interactions between concurrently administered drugs, contraindications, and different recommendations from guidelines for patients with multiple comorbidities and multiple indications for medication. Moreover, with an increased number of indications, the complexity of treatment regimens escalates because of numerous challenges associated with polypharmacy, the relevance of diverse mechanisms, and the heterogeneity of patient-related factors such as organ insufficiency, frailty, and patient's values and preferences.

7. Multimorbidity and Patient-Centered Care

A patient may present with hypertension, diabetes, chronic kidney disease, osteoarthritis, depression, and coronary disease. The treatment for such diseases according to the guideline may be complex and may have conflicts.

Integrated care therefore requires prioritization.

- Which condition poses the greatest immediate risk?
- Which intervention offers benefit across several conditions?
- Which medications have overlapping toxicity?
- How does treatment affect function and quality of life?
- What outcomes matter most to the patient?
- Can the therapeutic regimen realistically be followed?

WHO increasingly promotes integrated, person-centred primary health care encompassing a wide range of services from health promotion and prevention, to diagnosis, treatment, rehabilitation, and palliative care, over speciality-specific approaches to fragmented care.19

Primary care is central to this model because it has the potential to organise and integrate services around the individual, manage multiple risk factors and comorbidities, respond to downward referrals, address therapeutic itinerancy, undertake surveillance, monitor and mange medication use, and ensure continuity of care.20

8. Complex Disease Management: Severe Infection, Rehabilitation, and Palliative

Care

8.1 Severe Infection, Sepsis, and Antimicrobial Stewardship

Sepsis is an example of an entity where both mechanistic understanding and time-critical management are important. It is a potentially life-threatening condition due to a dysregulated host response to an infection resulting in dysfunction of one or more organs. The management approach is multifaceted, including timely initiation and adjustment of antimicrobial treatment, removal or modification of the putative infective focus, optimization of haemodynamics, organ support and continuous reassessment3

At the same time, the threat of antimicrobial resistance is growing at an alarming rate

WHO has warned that bacterial antimicrobial resistance was the direct cause of more than 4.7 million deaths globally in 2021 and that antimicrobial resistance was detected in 1 out of 6 laboratory-confirmed bacterial infections analyzed in 2023.2

Thus, the approach to managing individual infections needs to be nuanced to ensure that antimicrobials are given as soon as possible when there is a strong suspicion of a severe bacterial infection while avoiding antimicrobials when they are not needed and ensuring that those given are the most appropriate based on the clinical and microbiological findings.

The rapid evolution of diagnostics, the availability of genomic surveillance data about prevalent resistant pathogens, the need for vaccines, infection control measures, clean water and sanitation, antimicrobial stewardship, and a One Health approach to tackling antimicrobial resistance are all part of the solution.

8.2 Rehabilitation, Palliation, and Functional Outcomes

Disease management does not end when physiological parameters improve.

Patients who survive stroke, severe infections, cancer treatment, critical illness, an accident, or a significant surgical procedure can have a diminished quality of life after discharge due to disability, cognitive dysfunction, fatigue, emotional problems, or reduced independence. Therefore, the rehabilitation process has to be seen as an integral part of treatment, not an optional extras at the end.

Similarly, palliative care should not be seen as a final phase of treatment, but rather as an element that should ideally be incorporated alongside disease-modifying treatment, with management of symptoms, communication, psychosocial support, advance directives, and care planning.

An integrative approach to care is about ensuring that patients survive, but that they survive as fully and independently as possible, with manageable treatment and symptom burden, and with a level of function and quality of life appropriate to their individual circumstances.

9. Innovative Healthcare Strategies

9.1 Multi-Omics and Precision Health

While genomics is a single dimension, transcriptomics typically assesses RNA, whereas proteomics examines proteins, metabolomics – metabolites, epigenomics – epigenetic states, and microbiomics – the microbiome.

Multi – omics methodologies pursue the integration of such dimensions with clinical data to identify associations that are informative for the characterization of biological subtypes, thus enabling more accurate diagnosis, earlier detection of biomarkers, targets, and treatment responses.

Such an approach is particularly relevant in cases when the same diagnosis encompasses different disease mechanisms, while molecularly informed subtyping has the potential to transform syndromes into a set of categories associated with particular mechanisms.

The challenges of multi – omics are no longer exclusively technological but also pertain to consortia, harmonization, interpretation, clinical utility, cost – benefit analysis, ethical and legal aspects, and diversity.

9.2 Artificial Intelligence in Healthcare

Artificial intelligence has become one of the most prominent technologies in modern medicine.

The first medical applications of AI were limited to image interpretation. The modern systems, however, are capable of using text, laboratory results, images, physiologic data, and many other types of information. Generative artificial intelligence (AI) and medical foundation models can help summarize and document findings, propose differential diagnoses, respond to queries, and assist in research.20,21

Potential applications include:

- radiology and pathology interpretation;
- retinal imaging;
- ECG and physiological-signal analysis;
- risk prediction;
- early-warning systems;
- clinical documentation;
- medication review;
- triage;
- patient communication;
- trial matching;
- drug discovery;
- multimodal clinical decision support.

AI is also influencing drug development, including target discovery, molecular design, optimization, preclinical modeling, trial design, and pharmacovigilance.22

9.2.1 The Evidence Gap

High benchmark accuracy does not necessarily imply high clinical benefit to patients.

A diagnostic algorithm might function well on the sets used to develop and test it but perform significantly worse in different hospitals, on different hardware, with different patients and protocols, or by different clinicians. Variations in diagnostic prevalence, missing data, automation bias, miscalibration, hallucination, and behavioral changes all contribute to shifts in performance.

Recent assessments of medical AI suggest moving from benchmark performance to real-world effectiveness in prospective studies. As of 2026, claims of clinical utility and economic impact of many emerging medical AI technologies are not yet supported by evidence commensurate with the scale of the promises being made.23,24

9.2.2 Human-AI Collaboration

The strongest model may not be fully autonomous AI physicians but rather a human-AI system in which each component makes up for the deficiencies of the other.

Physicians bring to the table clinical judgment, examination, values, responsibility, communication, and an appreciation of uncertainty; AI brings computational power and pattern-recognition capabilities, information gathering and analysis, and monitoring.

Human oversight is likely to be critical for higher-level decision-making.

Ethical considerations highlight the importance of autonomy, safety, transparency, accountability, inclusiveness, equity, and sustainability.25

9.3 Digital Health, Wearable Technologies, and Remote Monitoring

Digital health is shifting portions of clinical observation from intermittent hospital visits to continuous or frequent measurement in everyday environments.

Wearable and connected devices can potentially monitor:

- heart rhythm;
- physical activity;
- sleep;
- glucose;
- oxygen saturation;
- blood pressure;
- respiratory parameters;
- body weight;
- medication adherence;
- symptom patterns.

Such tools can make it possible to detect deterioration at an earlier stage than is possible with standard care. For instance, serial measurements can signal the need for closer follow-up long before clinical decompensation becomes evident.

Telemedicine can provide patients with easier access to specialist care and reduce travel, whereas remote patient surveillance can contribute to the management of chronic diseases, particularly following discharge from hospital.

On the other hand, intensified surveillance can generate false positives and lead to unneeded investigations and

anxiety, as well as extra work for clinicians, and risks inequity if the technologies are unavailable or inaccessible to certain populations.
Digital medicine therefore requires actionable information, not merely more information.

10. Cell, Gene, and Regenerative Therapies

10.1 Cellular and Gene Therapies

Cell and gene therapies represent a fundamental paradigm shift from long-term pharmacologic modulation toward mechanistic alterations of cellular function or genetic material.
Gene-replacement approaches can provide therapeutic genetic information, whereas genome editing can introduce desired modifications into a patient's genome. Engineered cells can be generated ex vivo and reinfused into the patient, among them chimeric antigen receptor (CAR) T cells, which have been successfully directed against specific tumor targets
The clinical reality of cell and gene therapy has swiftly arrived; the Food and Drug Administration has a growing list of approved cellular and gene therapy products for the treatment of hematologic malignancies, inherited diseases, hemoglobinopathies, and other disorders.26
Moreover, engineered immune-cell therapies may have applications beyond immunodeficiency diseases and cancer, including autoimmune disorders; 2026 reviews discuss the potential for CAR-based approaches to achieve intensive B-cell depletion and immune system resetting.7
Nevertheless, these treatments raise major challenges:

- cytokine-release syndrome and neurological toxicities;
- infection risk;
- off-target effects;
- long-term safety;
- manufacturing complexity;
- conditioning regimens;
- access and cost;
- specialized infrastructure;
- durability of response.

CAR T-cell therapy in particular has a recognizable spectrum of acute and delayed toxicities that require specialized monitoring and management. 27
The future success of gene and cell therapy will therefore depend as much on manufacturing, safety, affordability, and health-system integration as on molecular efficacy.

10.2 Organoids, Tissue Engineering, and Regenerative Medicine

Three-dimensional organoid models derived from stem cells can reproduce selected structural and functional characteristics of human tissues more effectively than conventional two-dimensional cell culture.
Potential applications include:

- investigation of developmental biology;
- disease modeling;
- drug toxicity testing;
- infectious-disease research;
- individualized drug response;
- cancer modeling;
- regenerative medicine.

Patient-derived organoids may eventually realize their full potential in the context of developing functional precision medicine by enabling the testing of therapeutic intervention on a representative disease model prior to patient administration.
Tissue engineering and regenerative medicine fields aim to repair or replace biological structures by using cells, biomaterials, bioengineering principles and developmental biology.
Major translational hurdles are vascularization, maturation, reproducibility, scaling, immunology, manufacturing, tumorigenicity, and regulatory science.

11. Digital Twins and Learning Health Systems

11.1 Digital Twins and Computational Patient Models

A medical digital twin can be thought of as a continuously updating software model of a person or a biological system that uses patients' data.

Such a digital twin would be more than a simple risk calculator- it would utilize an individual's medical history and possibly genetic makeup to predict potential future health outcomes.

This could be used to test different treatment options, plan surgeries, assess risks, or keep track of a patients' health.

Though the idea is compelling, a digital twin is still a ways off to be truly realistic. Not only would this require accurate mechanistic patient models, but it would also need proper clinical data, data interoperability, uncertainty management, and most importantly proof that these tools actually improve outcomes.

Digital twins are currently little more than a burgeoning field and should be regarded as such for now.

11.2 Learning Health Systems

Traditional medical knowledge often moves from research to guidelines and then to practice through a slow linear process.

A learning health system attempts to create a continuous cycle:

Clinical care -> structured data -> analysis -> evidence generation -> decision support -> improved clinical care

Electronic health records, registries, pragmatic trials, real-world evidence, AI, pharmacovigilance, and implementation science can contribute.

This model can help answer questions that traditional randomized trials cannot address efficiently, such as rare adverse events, long-term effectiveness, and diverse populations, as well as issues of implementation in various settings.

The challenge is that observational data may contain confounding, bias, missingness, coding errors, and other weaknesses. Simply mining large databases is not a guarantee of reliable evidence.

Successful learning health systems will require rigorous epidemiology, analytic methods, informatics, data privacy and governance, and clinical judgment.

12. Population Health, Life-Course Integration, and Health Equity

12.1 Precision Public Health and Population-Level Integration

The future of medicine cannot be predicated solely on increasingly effective therapies for established diseases.

The concept of precision public health is to use epidemiology, genomics, environment, spatial, surveillance, and analytical data to improve prevention and management.15

There are numerous applications of this approach, ranging from the identification of populations at risk of an imminent outbreak to the optimization of screening programs, the assessment of environmental influences, and the examination of geographic variation in health.

Most important, although this approach can have a significant impact on health, it should be considered an addition to, rather than a replacement for, traditional public health approaches.

Drinking water, immunization, sanitation, tobacco control, healthy eating, air pollution abatement, and accessible and affordable primary care are interventions that have had an extraordinary impact on public health. A combination of broad approaches with more targeted ones is likely to be the most effective strategy for improving health. Thus, the most effective healthcare systems are the ones that focus on all populations with a combination of approaches while targeting specific groups when there is sufficient justification to do so.

12.2 Integration Across the Life Course

Disease risk accumulates through the life course.

Maternal health and childhood factors, such as nutrition, infections, social and environmental exposures, education, economic status, reproductive behaviors, occupational exposures, and aging, can contribute to the etiology of disease and affect health outcomes later in life.

A life-course approach therefore integrates women's and children's health across a continuum up to and including adulthood and emphasizes chronic disease prevention in adults, rather than considering these areas as distinct.

WHO has increasingly prioritized integrated approaches to noncommunicable diseases (NCDs) and reproductive, maternal, newborn, child, and adolescent health (RMNCAH).28

Integrating NCD services into RMNCAH is critically important in settings where patients may only engage with the health system during discrete encounters, where an opportunity for a broader range of services can be leveraged to improve health outcomes. During a single interaction, patients can be counseled on contraception, vaccinated, undergo screening for hypertension and diabetes, receive tobacco-cessation support, and be screened for cancer, depression, and other NCDs, as well as family planning counseling.

12.3 Health Equity and Social Determinants

In the context of the level of biological development of modern medicine, the question of ethics is extremely relevant.

Genome sequencing, artificial intelligence, cell therapy, telemedicine, and personalized medicine can reduce the burden on society; however, the cost of implementing these projects can be so high that only the elite can afford to use them.

The main determinants of health are a person's living conditions, working conditions, the state of the natural environment, education, the level of income and its balance, the availability of transport, health care, and social security.

In addition, they can affect a person's biology directly through the mechanisms of stress, exposure to pathogens, and the effects of food, treatment, or lack thereof, and timely detection of disease.

It is necessary to consider social determinants of health in a holistic approach to clinical medicine. Even if theoretically optimal treatment is available, but a patient cannot afford it, this does not mean that it is optimal in practice.

The burden of disease caused by non-communicable diseases in low- and middle-income countries is significantly higher than in high-income countries, reflecting inequities in health status between different population groups. This burden is associated with mortality from preventable and treatable diseases.1

13. Ethical, Regulatory, Governance, and Implementation Challenges Innovation often moves faster than regulation

13.1 Privacy

Genomic and health data can be deeply identifying. Large-scale data integration therefore requires robust consent, cybersecurity, access controls, governance, and transparent secondary-use policies.

13.2 Algorithmic Bias

An AI trained on biased data may present different results across different populations. The factors that contribute to such bias may include sampling bias, differences in treatment or devices, disparities in social demographics, or differences in clinical labeling between populations.

13.3 Explainability and Responsibility

If an algorithm recommends a diagnosis or treatment that causes harm, responsibility must remain identifiable. Clinical accountability cannot disappear inside a computational system.

13.4 Adaptive Technologies

Some AI systems may be developed after initial deployment. Thus, regulatory frameworks for controlling stationary devices need to be adjusted to ensure proper monitoring throughout the life cycles, updates, drifting, post-market performance, versions, and other aspects. FDA's guidance has been trending toward the life-cycle management of medical-device software that contains AI.29

13.5 Genetic Interventions

Genome editing involves ethical issues such as unintended effects, long-term consequences, germline modification, consent, access, and enhancement. Therapeutic genome editing of somatic cells must be clearly differentiated from germline modification.

Ethical governance should not be considered a barrier to innovation but rather a prerequisite for responsible clinical translation.

13.6 Implementation Science: Bridging Discovery and Practice

A frequent weakness of biomedical innovation is the assumption that an effective intervention will automatically

improve outcomes once introduced into clinical practice.
Implementation depends on:

- workflow compatibility;
- clinician acceptance;
- patient acceptance;
- training;
- infrastructure;
- reimbursement;
- cost-effectiveness;
- local disease burden;
- interoperability;
- regulatory requirements;
- supply chains;
- continuous quality measurement.

A diagnostic test that clinicians cannot interpret may increase uncertainty. An AI alert that triggers too frequently may be ignored. A molecular treatment requiring infrastructure unavailable outside specialist centers may have little population impact.
Implementation science therefore needs to be considered during development rather than after efficacy has already been demonstrated.

14. Future Directions, Major Challenges, and an Integrated Framework

14.1 From Disease Labels to Mechanistic Endotypes
Future classifications may increasingly group patients according to pathogenic pathways instead of symptoms or anatomy alone.
14.2 Earlier Detection
I think the emphasis for healthcare in the future would be placed on detecting a pre-clinical change either molecular or physiological before the tissue damage occurs.
14.3 Longitudinal Medicine
Continuous or repeated measurements may replace isolated snapshots for selected conditions, enabling dynamic estimation of risk.
14.4 Multimodal Decision Support
AI systems could eventually incorporate clinical notes, imagery, lab results, vital signs, pathology reports, genomics, and patient preferences. The literature published in 2026 already includes models that are able to adapt to the various domains, but contextually appropriate and validated solutions are still an active area of research,30
14.5 Mechanism-Based Prevention
Greater understanding of inflammation, metabolism, immunity, ageing, and environmental exposures may permit preventive interventions to be targeted before disease becomes clinically established.
14.6 More Curative Therapies
Gene correction, regenerative medicine, engineered cellular therapeutics, and tissue replacement offer the prospect that some chronic diseases are amenable to a single intervention or a small set of interventions. An expanding literature on gene therapy both illustrates the potential and underscores the importance of developing regulated, transparent, and sustainable approaches.31
14.7 Integrated Human-Technology Medicine
Technology should free the clinician from cognitive and administrative drudgery while not eliminating the human elements of empathy, communication, managing uncertainty, ethical decision making, and shared decision making. The future clinical encounter with technology may still benefit from human expertise, and it seems likely that the human elements will continue to be integral to the exchange as discussed below.
14.8 Major Challenges for the Next Generation of Medicine
Although there have been tremendous scientific advancements, there are several challenges that have been identified that would determine whether integrated medicine is a clinically relevant phenomenon.

The first limitation is biology, or the complexity of it, as many diseases originate from interactional networks, hence multiple biological processes.
The second limitation is heterogeneity, which refers to the fact that a successful treatment for one particular molecular category may not be tolerated or even received poorly by another.
The third limitation comes in the form of evidence, which means that newer technologies should not be evaluated on their technical capabilities but rather on how they affect established clinical processes and outcomes.
The fourth limitation is the current state of the healthcare ecosystem as it exists today, which is fragmented, and molecular stratification becomes irrelevant if there is no connectivity across the system.
The fifth limitation is related to the deluge of data that is available or being generated on a global scale, which has led to the realization that data abundance does not always translate into clinical intelligence.
The sixth challenge is affordability and accessibility, making sure equitable treatment is possible; if those aspects are not addressed, modern medicine only works for the select few, leaving everyone else with inadequate care.
Lastly, in terms of making integrated medicine a reality and precision medicine, there will always be clinical uncertainty, and although probabilities will shift, an absolute certainty will not become a characteristic of the discipline, and communication will remain as relevant as the technology itself.

14.9 An Integrated Framework for Modern Medicine

The considerations discussed above can be organized into five areas or layers:
Layer 1: Mechanism: Molecular, cellular, environmental, and physiological processes relevant to disease.
Layer 2: Measurement: The use of physical examination, laboratory and imaging tests, pathology, biomarkers, genomics, and digital tools to characterize these biological processes
Layer 3: Stratification: Determination of disease subtypes, severity, prognosis, treatment response, and risk of other conditions.
Layer 4: Intervention: Prevention, pharmacologic, surgical, rehabilitative, behavioral, cellular, genetic, supportive, and other approaches, tailored to individual patients by type and degree of intervention.
Layer 5: Learning: Use of information and data from patients' outcomes and other information to improve understanding of the disease and treatment approaches.
The considerations of patients' preferences and the impact of social, equity, ethical, safety, and economic factors should be embedded in all layers of care, not considered in addition to the other elements.

15. Conclusion

Modern medicine is witnessing a paradigm shift from isolated approaches to diseases based on fundamental mechanisms within specific organs toward a holistic understanding of disease at multiple levels, ranging from molecular and cellular to physiological, clinical, and socio-ecological, as well as technological platforms.

There are several biological themes that cut across diseases including genetic and epigenetic susceptibility and phenotypic expression, inflammatory pathways, altered metabolism and mitochondrial dysfunction, microbiome-host relationships, and biological ageing processes, among others.

At the level of care, there is a move towards intensified individualized assessment using clinical and molecular biomarkers, advanced and connected medical devices, and comprehensive follow-up. At the same time, treatment strategies are becoming more targeted, while the complexity and diversity of care configurations require coordinated, multidisciplinary, and patient-centered approaches across the continuum of care, including primary care, rehabilitation, and prevention.

The convergence of digital technologies, including artificial intelligence, multi-omics, cell and gene therapy, organoids, and advanced physiology-based modeling, holds great promise for the future of diagnostic and therapeutic medicine. Nevertheless, it is critical to ensure the tool's clinical utility and safety, as well as its regulatory, scalability, and cost-effectiveness. Similarly, the debate on the clinical and cost-effectiveness of artificial intelligence applications in healthcare can inform other areas of medicine. In my opinion, medicine and healthcare will not face a choice between the status quo and disruptive technology but rather adopt interdisciplinary methods to make treatments and procedures clinically validated and relevant in specific contexts and environments.

Therefore, the healthcare sector must be prepared to embrace interdisciplinary approaches, new methods, and evolving patient, professional, and research needs while prioritizing care, ethics, sustainability, accessibility, and personalization in the future.

References

1. World Health Organization. Noncommunicable diseases. WHO; 2025.
2. World Health Organization. Antimicrobial resistance. WHO; 2026.
3. World Health Organization. Sepsis. WHO; 2024.
4. Leighl NB. Osimertinib in stage III EGFR-mutated NSCLC-game, set, match. N Engl J Med. 2024;391:652-654. doi:10.1056/NEJMe2406495.
5. Hu T, Liu CH, Lei M, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct Target Ther. 2024;9:268.
6. Heneka MT, van der Flier WM, Jessen F, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25:321-352. doi:10.1038/s41577-024-01104-7.
7. Schett G, Xu H. Resetting autoimmune disease with CAR cell therapies. Nat Med. 2026;32:2007-2016. doi:10.1038/s41591-026-04430-6.
8. Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:124.
9. De Martino M, Rathmell JC, Galluzzi L, et al. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654-669. doi:10.1038/s41577-024-01026-4.
10. Wang B, Han J, Elisseeff JH, et al. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol. 2024;25:958-978. doi:10.1038/s41580-024-00727-x.
11. Keshavarz M, Xie K, Schaaf K, et al. Targeting the 'hallmarks of aging' to slow aging and treat age-related disease: fact or fiction? Mol Psychiatry. 2023;28:242-255.
12. Ma Z, Zuo T, Frey N, et al. A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation. Signal Transduct Target Ther. 2024;9:237. doi:10.1038/s41392-024-01946-6.
13. Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024;24:577-595. doi:10.1038/s41577-024-01014-8.
14. Jiao N, Zhu L, Zhu R. The search for authentic microbiome-disease relationships. Nat Med. 2024;30:1243-1244. doi:10.1038/s41591-024-02920-z.
15. Roberts MC, Holt KE, Del Fiol G, et al. Precision public health in the era of genomics and big data. Nat Med. 2024;30:1865-1873. doi:10.1038/s41591-024-03098-0.
16. Fitzgerald RC, Antoniou AC, Fruk L, et al. The future of early cancer detection. Nat Med. 2022;28:666-677.
17. Elhussein A, Baymuradov U, NYGC ALS Consortium, et al. A framework for sharing of clinical and genetic data for precision medicine applications. Nat Med. 2024;30:3578-3589. doi:10.1038/s41591-024-03239-5.
18. Lim SS, Semnani-Azad Z, Morieri ML, et al. Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. Nat Med. 2024;30:1874-1881. doi:10.1038/s41591-024-03033-3.
19. World Health Organization. Primary health care: a scalable solution to the noncommunicable diseases and mental health crisis. WHO; 2025.
20. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28:31-38.
21. Teo ZL, Thirunavukarasu AJ, Elangovan K, et al. Generative artificial intelligence in medicine. Nat Med. 2025;31:3270-3282. doi:10.1038/s41591-025-03983-2.
22. Zhang K, Yang X, Wang Y, et al. Artificial intelligence in drug development. Nat Med. 2025;31:45-59. doi:10.1038/s41591-024-03434-4.
23. Azad TD, Krumholz HM, Saria S. Principles to guide clinical AI readiness and move from benchmarks to real-world evaluation. Nat Med. 2026;32:802-804. doi:10.1038/s41591-025-04198-1.
24. Nature Medicine. Show us the evidence for the value of medical AI. Nat Med. 2026;32:1163. doi:10.1038/s41591-026-04389-4.
25. World Health Organization. Ethics and Governance of Artificial Intelligence for Health. World Health Organization.
26. US Food and Drug Administration. Approved Cellular and Gene Therapy Products. FDA; updated 2026.

27. Rejeski K, Hill JA, Dahiya S, et al. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025;31:2132-2146. doi:10.1038/s41591-025-03813-5.
28. World Health Organization. Integration Across the Life Course: Bridging Noncommunicable Diseases and Sexual, Reproductive, Maternal, Newborn, Child and Adolescent Health. WHO; 2025.
29. US Food and Drug Administration. Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. Draft Guidance for Industry and Food and Drug Administration Staff. FDA; 2025.
30. Li MM, Reis BY, Rodman A, et al. Scaling medical AI across clinical contexts. Nat Med. 2026;32:439-448. doi:10.1038/s41591-025-04184-7.
31. Nature Medicine. Keep up the momentum for gene therapies. Nat Med. 2026;32:769. doi:10.1038/s41591-026-04311-y.
32. Abdellatif M, Rainer PP, Sedej S, et al. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20:754-777. doi:10.1038/s41569-023-00881-3.
33. Zhao Y, Simon M, Seluanov A, Gorbunova V. DNA damage and repair in age-related inflammation. Nat Rev Immunol. 2023;23:75-89.
34. Tabara LC, Segawa M, Prudent J. Molecular mechanisms of mitochondrial dynamics. Nat Rev Mol Cell Biol. 2025;26:123-146. doi:10.1038/s41580-024-00785-1.
35. Kunath BJ, De Rudder C, Laczny CC, et al. The oral-gut microbiome axis in health and disease. Nat Rev Microbiol. 2024;22:791-805. doi:10.1038/s41579-024-01075-5.
36. Ozcam M, Lynch SV. The gut-airway microbiome axis in health and respiratory diseases. Nat Rev Microbiol. 2024;22:492-506. doi:10.1038/s41579-024-01048-8.
37. Weiner HL. Immune mechanisms and shared immune targets in neurodegenerative diseases. Nat Rev Neurol. 2025;21:67-85. doi:10.1038/s41582-024-01046-7.
38. Korczyn AD, Grinberg LT. Is Alzheimer disease a disease? Nat Rev Neurol. 2024;20:245-251. doi:10.1038/s41582-024-00940-4.
39. World Health Organization. Noncommunicable Diseases Progress Monitor 2025. World Health Organization; 2025.
40. World Health Organization. Global Antibiotic Resistance Surveillance Report 2025. World Health Organization; 2025.